20/20 Biolabs, Inc. (AIDX) stock
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3068% below fair value
$0.19−0.00 (-1.01%)
Close on Nov 18, 2026Market cap $2.37MP/E –Yield –
20/20 Biolabs shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
20/20 Biolabs's shares outstanding was 11M at Jun 30, 2026. For fiscal 2025 it was 5M, up 2.7% from the year before.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5M | +2.7% |
| FY2024 | Dec 31, 2024 | 5M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 11M | – |
| Q1 FY2026 | Mar 31, 2026 | 8M | – |
| Q2 FY2025 | Jun 30, 2025 | 5M | – |
| Q1 FY2025 | Mar 31, 2025 | 5M | – |
See a number that looks wrong?